Exploring potential drug−drug interactions between masculinizing hormone therapy and oral pre‐exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open‐label pharmacokinetic study in Thailand

Similar Items

• No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study
  by: Akarin Hiransuthikul, et al.
  Published: (2025)
• Prevalence and incidence of anal high‐grade squamous intraepithelial lesions in a cohort of cisgender men and transgender women who have sex with men diagnosed and treated during acute HIV acquisition in Bangkok, Thailand
  by: Supanat Thitipatarakorn, et al.
  Published: (2024)
• Assessing the acceptability of implementing a Screening, Brief Intervention and Referral to Treatment for alcohol use among transgender women in Bangkok, Thailand: A mixed‐method pre‐implementation study using the Consolidated Framework for Implementation Research
  by: Pongkwan Yimsaard, et al.
  Published: (2024)
• Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
  by: C. Busca‐Arenzana, et al.
  Published: (2024)
• Prevalence of people living with dementia with cyclic temporal pattern of behavioral and psychological symptoms of dementia in a tertiary memory clinic: A descriptive diary‐based study
  by: Tara Rak‐Areekul, et al.
  Published: (2024)